Literature DB >> 27115340

'Waterloo': when normal blood cells meet leukemia.

Hui Cheng1, Tao Cheng.   

Abstract

PURPOSE OF REVIEW: Mortality and morbidity associated with leukemia are largely due to frequently occurring cytopenias or the dysfunction of normal blood cells in patients. Our knowledge of how normal blood cells degenerate in response to leukemic cell infiltration has been quite limited. This review summarizes recent findings and discusses both extrinsic and intrinsic mechanisms underlying the suppression of normal hematopoiesis in leukemia. RECENT
FINDINGS: Recent studies have shown that leukemic cells are able to remodel the bone marrow niche by secreting specific cytokines or dampening its hematopoietic-supporting functions. In turn, a suitable microenvironment for leukemic cell proliferation but not for normal hematopoietic cell growth is created. Intrinsically, the leukemic condition impairs the normalcy of hematopoietic stem and progenitor cells and alters their signaling networks; consequently, it exhausts hematopoietic progenitor cells and forces stem cells into a more quiescent state, which would allow a reversible suppression of hematopoietic regeneration. The deepened quiescence of hematopoietic stem cells in leukemic marrow was achieved in part via transcription factor Egr3.
SUMMARY: These findings provide new insights into the mechanisms underlying hematopoietic suppression in response to leukemic cell outgrowth and offer new strategies to further improve current therapies for leukemias, placing more emphasis on the augmentation of normal hematopoietic regeneration when targeting leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27115340     DOI: 10.1097/MOH.0000000000000253

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  7 in total

1.  ANGPTL2-containing small extracellular vesicles from vascular endothelial cells accelerate leukemia progression.

Authors:  Dan Huang; Guohuan Sun; Xiaoxin Hao; Xiaoxiao He; Zhaofeng Zheng; Chiqi Chen; Zhuo Yu; Li Xie; Shihui Ma; Ligen Liu; Bo O Zhou; Hui Cheng; Junke Zheng; Tao Cheng
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

2.  Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis.

Authors:  Juan Carlos Balandrán; Jessica Purizaca; Jennifer Enciso; David Dozal; Antonio Sandoval; Elva Jiménez-Hernández; Leticia Alemán-Lazarini; Vadim Perez-Koldenkova; Henry Quintela-Núñez Del Prado; Jussara Rios de Los Ríos; Héctor Mayani; Vianney Ortiz-Navarrete; Monica L Guzman; Rosana Pelayo
Journal:  Front Immunol       Date:  2017-01-05       Impact factor: 7.561

3.  Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia.

Authors:  Ai Gao; Yuemin Gong; Caiying Zhu; Wanzhu Yang; Qing Li; Mei Zhao; Shihui Ma; Jianyong Li; Sha Hao; Hui Cheng; Tao Cheng
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

4.  Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs.

Authors:  Limei Wu; Qiqi Lin; Zhilin Ma; Fabliha Ahmed Chowdhury; Md Habibul Hasan Mazumder; Wei Du
Journal:  Leukemia       Date:  2020-05-04       Impact factor: 11.528

5.  The disruption of hematopoiesis in tumor progression.

Authors:  Xiaofang Wang; Yangqiu Li
Journal:  Blood Sci       Date:  2019-09-17

Review 6.  Emerging roles of extracellular vesicles in normal and malignant hematopoiesis.

Authors:  Guohuan Sun; Quan Gu; Junke Zheng; Hui Cheng; Tao Cheng
Journal:  J Clin Invest       Date:  2022-09-15       Impact factor: 19.456

7.  HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.

Authors:  Lulu Liu; Jingjing Zhang; Xianning Zhang; Panpan Cheng; Lei Liu; Qian Huang; Haihui Liu; Saisai Ren; Peng Wei; Cuiling Wang; Cuiyun Dou; Lulu Chen; Xin Liu; Hao Zhang; Mingtai Chen
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.